西藏药业跌2.01%，成交额1.60亿元，主力资金净流出677.88万元

Company Overview - Tibet Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone and was established on July 14, 1999, with its listing date on July 21, 1999 [1] - The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and 0.20% from other sources [1] Stock Performance - As of September 4, the stock price of Tibet Pharmaceutical decreased by 2.01%, trading at 48.79 CNY per share, with a total market capitalization of 15.726 billion CNY [1] - Year-to-date, the stock has increased by 39.13%, with a 1.75% rise over the last five trading days, 19.94% over the last 20 days, and 31.44% over the last 60 days [1] Financial Performance - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion CNY, representing a year-on-year growth of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million CNY [2] - The company has distributed a total of 2.258 billion CNY in dividends since its A-share listing, with 1.580 billion CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 8.08% to 45,200, while the average number of circulating shares per person increased by 8.79% to 7,132 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 2.5902 million shares, a decrease of 1.6084 million shares from the previous period [3]